| Budget Amount *help |
¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2014: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2013: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2012: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
|
|---|
| Outline of Final Research Achievements |
Multiple myeloma is the second most common hematological malignancy, and it is estimated that about 150,000 people in the world would die of myeloma every year. Although median survival is extended by development of new drugs, drug-resistant myeloma cells emerge in most of the patients, resulting in subsequent relapse of cancer. The cause of multiple myeloma is not known, and bone marrow transplantation is the only way to cure, albeit with a low success rate.
Our final destination is finding therapeutic sgRNAs to cure multiple myeloma based on TRUE gene silencing, which we have developed as a gene expression control technology. In this study, we elucidated partly how the candidate therapeutic sgRNA works, and showed that this sgRNA can reduce a tumor growth rate in a mouse model experiment.
|
